+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Retinopathy Market by Type (Proliferative DR and Non-Proliferative DR), by Management Type - Global Opportunity Analysis and Industry Forecast, 2014-2022

  • ID: 4612689
  • Report
  • Region: Global
  • 150 pages
  • Allied Analytics LLP
1 of 4
Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at the back of the eye. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast period due to increase in prevalence of diabetes worldwide, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment in focus on awareness which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs limit it. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are projected to provide several opportunities for the market growth.

The diabetic retinopathy market is segmented on the basis of type, treatment type, and region. Based on type, the market is bifurcated into proliferative DR and diabetic macular edema (DME). On the basis of treatment type, diabetic retinopathy market is segmented into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
This study provides the competitive landscape of the market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.

Diabetic Retinopathy Market Key Segments:

By Type

Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)

By Treatment Type

Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories
Alimera Science
Allergan plc
Ampio Pharmaceuticals.
Bayer AG
F. Hoffmann-La Roche
Novartis International AG
Pfizer
Regeneron Pharmaceuticals Inc.
Valeant Pharmaceutical

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Boehringer Ingelheim GmbH
KOWA Company, Ltd.
BCN Peptides S.A.
ThromboGenics NV
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2015
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Growing prevalence of diabetes
3.4.1.2. Increasing incidence of blindness due to diabetes
3.4.1.3. Growing geriatric population
3.4.1.4. Increasing awareness for treatment of diabetic retinopathy
3.4.2. Restraints
3.4.2.1. Extended approval time for drugs
3.4.2.2. Dearth of skilled ophthalmologists
3.4.3. Opportunities
3.4.3.1. Lucrative opportunities in the emerging economies
3.4.3.2. Emergence of combined therapies
3.4.4. Impact analysis
3.5. CLINICAL TRIALS

CHAPTER 4 DIABETIC RETINOPATHY MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PROLIFERATIVE DIABETIC RETINOPATHY
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. DIABETIC MACULAR EDEMA
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ANTI-VEGF DRUG
5.2.1. Market size and forecast
5.3. STEROID IMPLANTS
5.3.1. Market size and forecast
5.4. LASER SURGERIES
5.4.1. Market size and forecast
5.5. VITRECTOMY
5.5.1. Market size and forecast

CHAPTER 6 DIABETIC RETINOPATHY MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Canada
6.2.6. Mexico
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany
6.3.5. France
6.3.6. UK
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. India
6.4.7. South Korea
6.4.8. Australia
6.4.9. Rest of Asia-Pacific
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. South Africa
6.5.6. Saudi Arabia
6.5.7. Rest of LAMEA

CHAPTER 7 COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. Overview
7.1.2. Operating business segments
7.1.3. Business performance
7.1.4. Key strategic moves and developments
7.2. ALIMERA SCIENCE
7.2.1. Overview
7.2.2. Operating business segments
7.2.3. Business performance
7.2.4. Key strategic moves and developments
7.3. ALLERGAN PLC
7.3.1. Overview
7.3.2. Operating business segments
7.3.3. Business performance
7.3.4. Key strategic moves and developments
7.4. AMPIO PHARMACEUTICALS.
7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Business performance
7.4.4. Key strategic moves and developments
7.5. BAYER AG
7.5.1. Overview
7.5.2. Operating business segments
7.5.3. Business performance
7.5.4. Key strategic moves and developments
7.6. F. HOFFMANN-LA ROCHE
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Business performance
7.6.4. Key strategic moves and developments
7.7. NOVARTIS INTERNATIONAL AG
7.7.1. Overview
7.7.2. Operating business segments
7.7.3. Business performance
7.7.4. Key strategic moves and developments
7.8. PFIZER
7.8.1. Overview
7.8.2. Operating business segments
7.8.3. Business performance
7.8.4. Key strategic moves and developments
7.9. REGENERON PHARMACEUTICALS INC.
7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Business performance
7.9.4. Key strategic moves and developments
7.10. VALEANT PHARMACEUTICAL
7.10.1. Overview
7.10.2. Operating business segments
7.10.3. Business performance
7.10.4. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Diabetic Retinopathy Market Report, states that the global market the diabetic retinopathy market was valued at $966 million in 2015, and is projected to reach $2,490 million by 2022, growing at a CAGR of 14.4% from 2016 to 2022. The proliferative diabetic retinopathy segment accounted for more than half of the total market in 2015.

Diabetic retinopathy (DR) is a medical condition of the eye prevalent in diabetic individuals. It is mainly caused due to damage of the blood vessels of the reti. Without timely treatment, the disease leads to bleeding in the eyes, cloudy vision, and may even destroy the reti. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The market is expected to witness significant growth during the forecast period due to factors such as increase in prevalence of diabetes, growth in geriatric population, rise in incidence of blindness due to diabetes, and augment in focus on awareness, which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs can pose as a major obstacle for the growth of the diabetic retinopathy market. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are anticipated to provide several opportunities for the market growth.

Proliferative diabetic retinopathy segment accounted for a major market share (more than half) in 2015 as the disease is one of the leading causes of blindness in diabetic patients. Moreover, nearly 20% of the people suffering from diabetic retinopathy (any type) have proliferative diabetic retinopathy.

Key findings of the Diabetic Retinopathy Market

Based on treatment type, laser surgeries segment accounted for more than two-fifths of the total market in 2015.
Anti-VEGF drugs accounted for more than one-third of the total market in 2015.
Diabetic macular edema segment is expected to grow at a high CAGR of 14.6% from 2016-2022
Asia-Pacific is expected grow at a high CAGR of 15.4%, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of diabetic retinopathy.

North America accounted for majority of the share (nearly two-fifths) in the market in 2015, and is expected to remain domint throughout the forecast period. This is attributed to the increase in incidence of diabetes along with the rise in geriatric population, increased patient awareness about diabetic retinopathy, and favorable reimbursement framework for retinopathy procedures. In addition, presence of highly sophisticated healthcare infrastructure is anticipated to provide new growth opportunities for the key players in this market.

The major companies profiled in the report include Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis Intertiol AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical. Other key players in the value chain include Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., and ThromboGenics NV.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4612689
Adroll
adroll